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The sodium pump is a ubiquitous cell surface enzyme, a Na, K ATPase, which maintains
ion gradients between cells and the extracellular fluid (ECF). The extracellular domain of
this enzyme contains a highly conserved binding site, a receptor for a plant derived family
of compounds, the digitalis glycosides.These compounds inhibit the enzyme and are used
in the treatment of congestive heart failure and certain cardiac arrhythmias. The highly
conserved nature of this enzyme and its digitalis receptor led to early suggestions that
endogenous regulators might exist. Recent examination of this hypothesis emerged from
research in two separate areas: the regulation of ECF volume by a natriuretic hormone
(NH), and the regulation of peripheral vascular resistance by a circulating inhibitor of vas-
cular Na, K ATPase.These two areas merged with the hypothesis that NH and the vascular
Na, K ATPase inhibitor were in fact the same entity, and that it played a causative role in
the pathophysiology of certain types of hypertension.The possibility that multiple endoge-
nous digitalis-like factors (EDLFs) exist emerged from efforts to characterize the circulating
enzyme inhibitory activity. In this review, the development of this field from its beginnings
is traced, the current status of the structure of EDLFs is briefly discussed, and areas for
future development are suggested.
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BACKGROUND
The regulation of salt and water excretion by the kidneys has occu-
pied investigators since at least from the beginning of the 20th
century. Highlights of these investigations are documented in early
reviews of the subject, notably those by Epstein (1) and Smith (2)
in the 1950s. These reviews supported the existence of a receptor-
integrator-effector reflex by which changes in some component of
the extracellular fluid (ECF) volume (“volume receptors”) caused
appropriate changes in renal sodium excretion. Both “efferent fac-
tors,” the numerous hemodynamic, humoral, and neural factors
known to directly affect renal sodium excretion, and “afferent
factors,”the stimuli that activate the efferent factors,were reviewed.
Smith, separating the factors influencing free water excretion
from those affecting sodium excretion, considered the mechanism
of the latter as being similar to the former. Based on these and
other evolutionary considerations, he postulated that the proposed
effector for sodium excretion, which he called “Hormone X”, was
an anti-natriuretic hormone, analogous to antidiuretic hormone,
which had evolved to conserve sodium as our primitive ancestors
made their “ascent through the brackish waters of the estuary/to
the salt poor lakes and ponds” (Strauss) (2). Aldosterone had
been identified in the early 1950s, so Smith’s Hormone X was
clearly proposed as an additional volume sensitive sodium retain-
ing hormone, decreased levels of which would cause natriuresis in
response to increased ECF volume.
At the time of Smith’s review, it was well established that two
factors were preeminent in controlling renal sodium excretion,
glomerular filtration rate (GFR), and aldosterone. Thus, Smith’s
review set the stage for exploration for a “third factor,” a term
which did not originate with Smith. The earliest investigators to
use the term in print, if not the first, were Bricker et al., who
were searching for the mechanisms contributing to the progres-
sive increase in the absolute rate of sodium excretion per nephron
as the nephron population decreased in chronic renal failure (3).
Bricker et al. were the first to recognize that similar mechanisms
might contribute to both volume expansion natriuresis and the
renal adaptation to chronic renal failure.
THE CONCEPT OF NATRIURETIC HORMONE
Four years after Smith’s review, the mechanism of “volume expan-
sion natriuresis” was addressed in a classic paper by deWardener
et al. published in 1961 (4). They showed that natriuresis caused
by saline infusion in dogs given large doses of mineralocorticoid
was not abolished when GFR was reduced below initial levels by
constriction of the aorta above the renal arteries. Furthermore,
they showed that blood circulated from volume expanded dogs
(donor) to euvolemic dogs (recipient) caused natriuresis in the
recipient. Based on these studies, deWardener et al. suggested that
volume expansion increased the circulating level of some natri-
uretic substance, and the concept of “natriuretic hormone” was
born.
Three problems quickly emerged after this ground-breaking
study was published. First, although the cross circulation studies
were careful to control the volume of the recipient dog, the pos-
sible effects of blood dilution by the saline infusion in the donor
dog were not. In addition, the possibility that the natriuresis in the
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recipient dog might be due to suppression of an anti-natriuretic
factor as suggested by Smith had not been definitively eliminated.
Each of these issues was addressed in the burst of work in other
laboratories that followed the original paper by de Wardener et al.
Importantly, these investigators effectively dealt with the dilution
issue in a subsequent cross circulation study in which the recipi-
ent dog was infused with blood from a reservoir in which blood
from both donor and recipient was in equilibrium (5). Other stud-
ies addressing the issue of dilution were published by Lichardus
et al. and others (6). Studies of the effects of blood dilution on
renal sodium excretion subsequently led to exploration of the so
called “physical factors” on renal tubular sodium reabsorption by
a number of laboratories (7).
In essentially all refinements of the cross circulation studies,
the natriuresis in the recipient was much less than that in the
donor animal, a finding that was never entirely explained, but some
interesting observations were made. For example, response in the
recipient was increased by infusing blood from the donor into the
aorta just above the renal arteries (8), suggesting a short biologic
half-life of the circulating natriuretic factor (9). Also, recipient
response was enhanced by preventing the donor from excreting the
administered volume load, suggesting some effect of “sustained”
volume expansion, an interesting but poorly defined concept that
has not been explored further (10).
MECHANISMS OF NATRIURESIS
The cross circulation studies did not distinguish between the
presence of a natriuretic substance versus suppression of an anti-
natriuretic substance. To make that distinction, a number of
laboratories reported natriuretic activity in plasma, urine, and/or
kidney tissue of volume expanded animals (11–13), the mecha-
nism of which drew immediate interest. The question was whether
the factor caused changes in renal hemodynamics or directly inhib-
ited tubular sodium transport systems. The first studies suggesting
the latter were performed by Bricker et al. in which inhibition
of p-aminohippurate (PAH) transport by rabbit kidney cortical
slices was inhibited by plasma from volume expanded subjects
(14). Inhibition of transport in renal tubular epithelium was
subsequently shown in isolated tubular cells (15).
Other early studies utilized anuran membranes as models of
renal tubular sodium transport. Cort and Lichardus reported inhi-
bition of sodium transport as measured by Ussing’s short circuit
current (SCC) technique in isolated frog skin by deproteinized,
concentrated plasma extracts with very high sodium concentra-
tions (16). In more extensive studies using plasma ultrafiltrates
with physiological salt concentrations from volume expanded
dogs, Buckalew et al. in 1970 showed similar effects on toad bladder
SCC of bufo marinus (17). Ussing and others had demonstrated
that the SCC in anuran membrane was due to active sodium trans-
port, and could be inhibited by ouabain. The demonstration that
the putative natriuretic hormone inhibited tubular transport and
SCC set the stage for investigation of the effect of this factor or
factors on Na, K ATPase. The initial attempts to relate natriuretic
hormone (NH) to Na, K ATPase inhibition were unsuccessful.
In the best documented studies, Katz et al. were unable to show
inhibition of the enzyme in renal cortical microsomes from vol-
ume expanded dogs and rats, or an effect of plasma dialyzates
from these animals on renal microsomal Na, K ATPase isolated
from euvolemic animals (18). However, Gonick et al. subsequently
reported that a natriuretic fraction extracted from renal tissue and
plasma of volume expanded animals inhibited SCC in frog skin
and ouabain sensitive Na, K ATPase isolated from whole rat kidney
(19, 20).
Studies of the effect of plasma, and extracts of plasma and
urine of volume expanded subjects on sodium excretion in assay
animals, usually rats, demonstrated two basic patterns that differed
primarily in time to peak and duration of effect. The shorter acting
pattern showed an immediate onset, a peak effect in 40–60 min,
and duration of about 120 min (21, 22). The longer-acting pat-
tern exhibited a delay in onset of 10–60 min, a peak effect in 2–3 h,
and duration longer than 3 h (22). Some initial purification studies
indicated that the more rapidly acting factor was found in fractions
containing low molecular weight substances, and the longer act-
ing factor appeared in fractions containing high molecular weight
substances (23).
NATRIURETIC HORMONE AS INHIBITOR OF Na, K ATPase
Two major developments in the late 1970s and early 1980s caused a
shift in the direction of NH research. The discovery in 1981 of atrial
natriuretic factor (ANF) by DeBold et al. (24) and its subsequent
characterization as a peptide signaling cascade present in many
organs displaced most other lines of investigation with regard to
the existence and nature of a NH. Early studies did not show an
effect of ANF on Na, K ATPase (25, 26); however, subsequent stud-
ies revealed a more complex situation (27–29). Nevertheless, it was
clear from the early work that ANF and the natriuretic inhibitor
of renal epithelial transport systems dependent on Na, K ATPase
were two entirely different systems. However, very little further
work on the non-ANF NH hypothesis was performed. Instead, the
focus shifted to the second major development, namely, that NH
might be an inhibitor of vascular Na, K ATPase that could also be
a causative factor in certain types of hypertension.
The suggestion that some types of hypertension, especially
those associated with ECF volume expansion, might be due to
a circulating inhibitor of vascular Na, K ATPase evolved from
studies of the phenomenon of potassium-induced vasodilation.
Overbeck et al. showed that the dilator response to potassium,
but not to other agents, was suppressed in the forelimb of the
rat with two kidney, one clip hypertension and the dog with one-
kidney, one-wrap hypertension (30). Subsequent studies showed
that potassium-induced vasodilation was completely blocked by
ouabain, leading to the hypothesis that the vasodilation was due to
stimulation of vascular smooth muscle Na, K ATPase. According to
this hypothesis, stimulation of the electrogenic sodium pump led
to hyperpolarization, decreased voltage sensitive influx of calcium,
and hence vascular relaxation (31).
Reduced serum potassium produced identical effects in the
opposite direction. That is, hypokalemia was associated with vaso-
constriction and suppressed Na pump activity, suggesting a cause
and effect relationship. As predicted by this paradigm, vascular
depolarization was found in several volume expanded hyperten-
sion models. Thus, the hypothesis was proposed that vasocon-
striction leading to hypertension might be caused by generalized
inhibition of vascular Na, K ATPase activity (32). In a further
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refinement of the hypothesis in 1976, based on a review of then
existing evidence for a humoral factor that slowly increased blood
pressure in both animal models and humans with hypertension,
Haddy et al. proposed that Na, K ATPase inhibition in vascular
tissue, and hence vasoconstriction, might be due to a circulat-
ing factor (33). They, in fact, proposed in that review that the
postulated circulating inhibitor of Na, K ATPase might be “natri-
uretic hormone.” Thus, the two fields of ECF volume regulation
and regulation of vascular tone in volume expanded models of
hypertension were brought together in the search for a common,
explanatory factor (Figure 1).
A unifying explanation for the connection between vascular
tone, intracellular calcium concentration, and the sodium pump
was proposed by Blaustein in 1977 (34). The model was based on
the presence of a Na–Ca exchanger located in the plasma mem-
brane, driven by the intracellular–extracellular sodium gradient.
According to the hypothesis, supported by kinetic calculations
(34), inhibition of the sodium pump by the NH would cause
increased vasoconstriction by inhibiting the outward transport
of calcium by the Na–Ca exchanger.
VOLUME EXPANDED MODELS OF HYPERTENSION
The NH hypothesis of hypertension raised the question of how
volume regulation by a potentially vasoconstrictor NH occurred
in normal versus hypertensive subjects. Volume expanded mod-
els of hypertension involved some manipulation that reduced
the ability of the kidney to excrete sodium. This approach was
based on the concept proposed by Guyton et al. (35) that all
hypertension was caused by an abnormal relationship between
blood pressure and renal sodium excretion. According to this
hypothesis, in normal subjects, renal adaptation to increases and
decreases in sodium intake occur without any or with only small
changes in systemic blood pressure. However, increased blood
pressure is required to maintain ECF volume regulation in the
presence of impaired renal sodium excretion through the phe-
nomenon of “pressure diuresis.” Guyton postulated the rise in
pressure was due to a volume induced increase in cardiac output
and the consequent “long term autoregulation” (i.e., vasocon-
striction) that ensued. Thus, ECF volume is maintained at the
expense of increased peripheral vascular resistance and high blood
pressure.
Regulaon of Extra-
Cellular Fluid Volume
Natriurec Hormone
Renal Tubular
Na, K ATPase Inhibitor
Regulaon of
Vascular Resistance 
Vascular Ion Transport 
In Hypertension
Vascular Na, K ATPase
Inhibitor
EDLF
Cardenolides/Bufodienolides
Hypertension/Preeclampsia
Congesve Heart Failure
Chronic Renal Failure 
FIGURE 1 |The concept of an endogenous digitalis-like factor
(EDLF) that inhibits Na, K ATPase in a manner similar to the
cardiac glycosides developed from two lines of investigation (see
text), the response of renal sodium excretion to extracellular fluid
volume expansion, and the regulation of peripheral vascular
resistance in hypertension. Research on the identity of EDLF
indicates that mammalian species synthesize two classes of steroids
that are either identical to, or analogs of those found in plants
(cardenolides) and toads (bufodienolides). Evidence suggests that one
or more of these compounds may be involved in the pathophysiology
of various hypertensive disorders, chronic renal failure, and congestive
heart failure.
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Based on this theory, several investigators proposed a unifying
hypothesis incorporating NH that explained many observations
then existing in the literature (36, 37). According to this formula-
tion, the defect in renal response to increases in sodium and water
intake in hypertensive subjects leads to increases in NH, vascular
Na, K ATPase inhibition, vasoconstriction, and increased blood
pressure. Volume homeostasis is maintained in the presence of a
defect in renal sodium excretion by both the rise in blood pres-
sure through the mechanism of pressure natriuresis, and by the
effect of the NH to inhibit renal tubular sodium reabsorption.
The difference between hypertensive and normotensive subjects
was, as suggested by deWardener and MacGregor, that the for-
mer would be in a “state of continuous correction of a slightly
expanded extracellular volume,” resulting in a sustained elevation
of NH (37). While this concept may have some general validity, the
role of EDLF differs in various forms of hypertension (see below).
ENDOGENOUS DIGITALIS-LIKE FACTOR
Because of the suggestion that NH might be an inhibitor of Na,
K ATPase, it was subsequently referred to as “ouabain-like” or
“digitalis-like.” This terminology became more than nomencla-
ture as the field turned to proving the true digitalis-like nature of
the circulating factor.
THE CONCEPT OF ENDOGENOUS DRUG-LIKE COMPOUNDS
The demonstration that the specificity and actions of some drugs
were due to drug binding to stereospecific receptors had led
to speculation that naturally occurring endogenous compounds
existed that bound specifically to these receptors (38). The discov-
ery of endogenous opioids was a direct result of this hypothesis
(39). In 1976, Ginzler et al. proposed, as an extension of this con-
cept, that antigen–antibody binding specificity might be analogous
to drug-receptor binding specificity (40). That is, an antibody spe-
cific for a drug might recognize the same structure as the specific
receptor for that drug, and could act as a “surrogate” receptor.
This hypothesis had at least two interesting implications. First,
antibodies to drugs might recognize endogenous compounds that
utilize the same receptor as the drug; and second, antibodies to
drugs (or endogenous compounds) might be used to block the
effects of those compounds by displacing them from their recep-
tor. The second possibility had already been anticipated by a
number of investigators including the demonstration that digoxin
antibodies would reverse the clinical manifestations of digoxin
intoxication (41).
Based on these concepts, Gruber et al. showed in 1980 that
plasma of volume expanded dogs but not euvolemic dogs con-
tained a factor that cross reacted with digoxin antibodies in
a specific fashion; i.e., the dose response curve in the digoxin
radioimmunoassay (RIA) of the endogenous factor was parallel
to that of authentic digoxin (42). Furthermore, plasma extracts
containing the digoxin immunoreactive compound inhibited Na,
K ATPase, providing further evidence for a true EDLF that had
some structural and functional similarity to digoxin. The finding
also suggested that digoxin RIAs could be used to study plasma
levels of this factor and numerous studies of mammalian“digoxin-
like” factor were soon published (43). However, studies using this
approach are subject to non-specific cross reactivity of various
interfering substances in the digoxin RIA and have led to some
confusion (44, 45). Interestingly, the first demonstration of an
endogenous substance that cross reacts with digoxin antibodies
was in newborns, who were suspected of having been poisoned
with digoxin (46).
CHARACTERIZATION OF EDLF
Subsequent to the work briefly described above, numerous
attempts have been made to purify and identify the principal fac-
tor responsible for the digitalis-like factor demonstrated in volume
expanded subjects. According to the initial hypothesis, a truly
endogenous, natriuretic, hypertension promoting digitalis-like
factor would have the following characteristics. First of all, it would
be synthesized endogenously, and secreted under the control of rel-
evant physiological or pathophysiological stimuli. Second, it would
inhibit renal and vascular Na, K ATPase in a “ouabain-like” fash-
ion; that is, it would bind to the same receptor and have similar
effects on the enzyme as ouabain. Thirdly, its inhibition of renal
tubular and vascular Na, K ATPase would cause natriuresis and
vasoconstriction, respectively. Unfortunately, attempts to identify
such a factor have been complicated by the fact that inhibition of
the enzyme in various assay systems is a non-specific effect of many
diverse compounds (47). As a result, numerous candidate struc-
tures have been identified, including steroids, lipids, peptides, and
a variety of other novel compounds (45, 48, 49). A complete review
of these reports is beyond the scope of this paper. Rather, we have
chosen to focus on a class of compounds that are “digitalis-like”
steroids, and which meet the theoretical criteria outlined above,
with one exception. They have not been shown unequivocally to
be “endogenous” since their synthetic pathway has not been com-
pletely elucidated, although preliminary studies suggest they are
synthesized in the adrenal gland (50–53).
In 1991, Hamlyn et al. reported purification of a com-
pound indistinguishable from ouabain by mass spectroscopy from
300 l of human plasma (54). Subsequent work seemed to con-
firm this observation and indicated that mammalian ouabain
is present in multiple body fluids and tissues. However, the
issue of whether mammalian tissues contain authentic ouabain
has remained highly controversial (55–57) despite substantial
evidence in support of this finding (58).
Amphibian species have been known for many years to syn-
thesize a number of different steroids called bufodienolides that
inhibit Na, K ATPase in a manner similar to the cardenolides (59).
Dienolides differ from cardenolides in the structure of the lactone
ring, which contains six members and two unsaturated double
bonds compared to five members and one double bond in the
cardenolides (43). Both cardenolides and dienolides have a 14 β
hydroxyl group and a cis tertiary configuration of the C/D ring
junction. Lichstein et al. identified a bufodienolide in toad skin
and plasma as resibufogenin (60). They also demonstrated that
the concentration of dienolides in toad skin was regulated by the
salt content and osmolality of its aquatic environment (61, 62).
Bagrov et al. purified a digitalis-like compound from toad
venom (63), which they subsequently identified as a previously
described bufodienolide marinobufagenin (MBG) (64). Sub-
sequently, purification of a substance from urine of patients
after an acute myocardial infarction by high pressure liquid
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chromatography confirmed a structure indistinguishable from
authentic MBG (65). Using a polyclonal antibody to toad MBG,
they demonstrated increased concentration of a compound rec-
ognized by that antibody in plasma of volume expanded dogs (66)
and rats (67), and patients with preeclampsia (68). Using anti-
bodies specific for ouabain and MBG, they demonstrated that
mammalian plasma contains both ouabain-like and MBG-like
compounds (66). Subsequent work has demonstrated that the
MBG-like compound meets essentially all the criteria originally
postulated for the EDLF-type NH described above (69, 70).
Yoshika et al. have shown that MBG immunoreactivity secreted
by adrenomedullary derived cells in tissue culture is composed of
at least two compounds, MBG and a related compound marinobu-
fotoxin (MBT) (71). MBT was shown to increase blood pressure
when administered intraperitoneally to rats (71).
EDLF AND HYPERTENSION
Using multiple assays for EDLF, numerous studies have attempted
to show some correlation between plasma EDLF levels and the
blood pressure in human and experimental hypertension, details
of which have been previously reviewed and are beyond the
scope of this paper (69, 72–80) Many of these studies have relied
on measurements using RIA technology with antibodies raised
against the compound(s) of interest. As noted, these studies are
subject to cross reactivity with compounds other than those
to which the antibody was raised. Despite these problems, it
seems likely that some EDLF(s) are elevated in some forms of
human and experimental hypertension and may play a role in its
pathophysiology.
Although most studies of the role of EDLF in hypertension have
focused on the circulating factors, it seems likely that endogenous
ouabain plays a role in certain types of hypertension through a
pathway in the central nervous system (CNS). EDLF has been
demonstrated in hypothalamic and pituitary extracts of rats, a
compound (or compounds) that crossreacts with a polyclonal
anti-ouabain antibody (81). Extensive studies by Huang et al.
have shown increases in this compound in the hypothalamus
of Dahl salt-sensitive rats (82), spontaneously hypertensive rats
(SHR) (83), and normal rats in which blood pressure is increased
by an increase in cerebrospinal fluid sodium concentration (84).
The critical role of brain EDLF in each of these models was
demonstrated by prevention of the rise in blood pressure by CNS
administration of a commercially available antigen binding frag-
ment (FAB) of an antidigoxin antibody known to cross react with
EDLF (Digibind®) (see below). A further complexity in the hyper-
tension promoting CNS EDLF system has been demonstrated by
studies of central infusion of angiotensin II in rats. This hyper-
tension provoking maneuver causes an increase in circulating
endogenous ouabain through activation of a neuronal pathway
involving central aldosterone (85).
An integrated role for both endogenous cardenolides and bufo-
dienolides in hypertension in Dahl salt-sensitive rats is suggested
by studies showing that release of MBG is controlled by the CNS
ouabain pathway discussed above (86). Further studies on the role
of CNS pathways in the pathophysiology of hypertension, and in
controlling circulating endogenous digitalis-like factors (EDLFs)
and blood pressure should be of interest.
REVERSAL OF EDLF EFFECTS BY FUNCTIONAL ANTAGONISTS
Several functional antagonists of EDLF have been reported to
reverse the effects of Na, K ATPase inhibition in various clini-
cal and experimental situations, among which are anti-dogoxin
and anti-ouabain antiserum, and two steroid compounds, rosta-
furoxin and resibufagenin, that may be receptor antagonists of one
or another component of EDLF.
Digibind® is a purified FAB of a sheep anti-digoxin antibody
developed for the treatment of digoxin intoxication that is no
longer available commercially. Studies using Digibind® as a probe
to assess the possible role of EDLF in hypertensive subjects assume
that it will cross react with EDLF, and that in large enough doses
will displace EDLF from its receptor, analogous to its effect in
digoxin toxicity. A number of studies are compatible with this
formulation. Krep et al. showed that Digibind® reduced blood
pressure in the DOCA-salt rat model (87). Kaide et al. obtained
the same results in a 5/6 reduced renal mass model (88). In the lat-
ter study, no effect of Digibind® on blood pressure was observed in
sham-operated controls, suggesting that the blood pressure reduc-
tion was not due to some non-specific or toxic effect of Digibind®
such as an anaphylactoid reaction. Mann et al. had suggested the
latter, but their studies were done with commercial preparations
other than Digibind® (89). In addition to these in vivo stud-
ies, Krep et al. showed that Digibind® reversed the contraction
response of isolated aorta to an EDLF isolated from peritoneal
dialysis fluid (90). Digibind® has also been reported to reduce
blood pressure in several hypertension models when given directly
into the CNS (84, 91), to block the natriuresis of saline infusion in
dogs (66), and to improve neonatal outcomes in fetuses born to
patients with preeclampsia (92).
Antibodies against other glycosides have also been shown to
lower blood pressure in animal models. Anti-ouabain antibodies
had no effect on blood pressure in normal rats (93). However,
immunization against ouabain prevented the development of
hypertension in Dahl salt-sensitive rats (94), and reduced sodium
excretion in normal rats (93). Also, administration of MBG anti-
bodies lowered blood pressure in Dahl salt-sensitive rats (95).
These studies suggest that whatever EDLF might be, whether sin-
gle or multiple compounds, it cross reacts with antibodies against
several candidate EDLFs.
In addition to the work with antibodies, two possible receptor
antagonists of EDLF have been reported. Rostafuroxin® is a dig-
itoxigenen derivative that selectively displaces ouabain from the
Na, K ATPase receptor (96). The compound lowered blood pres-
sure in Milan hypertensive rats (97), but failed to lower blood
pressure in clinical trials in essential hypertension in humans
(77). Resibufogenin (RBG) is a bufodienolide isolated from toad
skin (60) and the traditional Chinese medication Chan Su made
from dried toad venom (98). RBG has a structure that only dif-
fers from MBG by one oxygen atom on the 5-position of the
steroid nucleus (99). Although RBG has “digitalis-like activity”
(inhibits in vitro Na, K ATPase activity and ouabain binding) (60),
RBG has been shown to lower blood pressure in rat models of
preeclampsia and DOCA-salt hypertension (100), both of which
have elevated levels of MBG. These data suggest RBG antagonizes
at least some effects of MBG, but the exact mechanism has not
been elucidated.
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Although similar in structure, different cardenolides and bufo-
dienolides have surprising and unpredictable species and tissue
differences in their biological actions (101–103), including antag-
onism of each other’s effects (104–107). The mechanism of the
latter phenomenon has been extensively studied by Song et al.
(105). They proposed a complex set of models in which α and
β subunits of Na, K ATPase can function as tetraprotomers with
varying degrees of aggregation and pump inhibition. This con-
cept may lead to an entirely new method of manipulating sodium
pump function that could have clinical implications.
It should also be noted that ACTH induced hypertension in
rats can be prevented by making the α-2 Na, K ATPase receptor for
cardiac glycosides resistant to those compounds through genetic
manipulation (108). This clearly implicates endogenous Na, K
ATPase inhibitor(s) in the etiology of this type of experimental
hypertension.
SUMMARY IN RETROSPECT AND FUTURE DIRECTIONS
The search for a factor that regulates renal sodium excretion in
response to increased blood volume, a NH, stimulated by the
experiments of deWardener et al. (4) has produced a huge body
of literature, which can no longer be reviewed in a single arti-
cle. This review, an update of an earlier one (109), emphasizes
how the search for a NH converged with studies of the mecha-
nism of increased vascular resistance in hypertension, resulting
in the discovery of EDLF(s) (Figure 1). This important discov-
ery has widespread physiologic and pathophysiologic implications
and explains, at least in part, the highly conserved nature of the
ouabain binding site on membrane Na, K ATPase.
The fact is that, after all the work briefly summarized here, an
amazing degree of complexity to a relatively simple if naïve concept
has emerged. Regarding the original NH proposal of deWardener
et al., no single entity has emerged that fits their hypothesis, and
new physiologically relevant natriuretic factors may yet be discov-
ered (9). Atrial natriuretic peptides are clearly volume sensitive
natriuretic factors that likely play some role in the renal response
to acute volume expansion. ANPs have multiple effects includ-
ing vasodilation, and one or more of these peptides probably play
some role in the pathophysiology of hypertension and conges-
tive heart failure (110). Interactions between ANP and several
EDLFs have been demonstrated, which have potentially impor-
tant physiologic and pathophysiologic implications (27, 111, 112),
and further work in the area can be anticipated.
Ouabain, MBG, and other bufodienolides continue to be inves-
tigated as putative physiological regulators of renal and cardio-
vascular function, but no clear integrating hypothesis has yet
emerged. MBG appears to fit the criteria for the circulating fac-
tor proposed by the original NH hypothesis better than ouabain
(72), but ouabain is clearly involved in the regulation of sodium
excretion by the CNS and further work on this system is antici-
pated (9, 73). The intrarenal mechanism by which bufodienolides
cause natriuresis, which involves the recently discovered signal-
ing function of Na, K ATPase, should be of ongoing interest
(113). The synthetic pathways and tissue(s) origin for the various
EDLFs have not yet been completely determined, and high priority
should be given to this project (58). If EDLFs play a role in nor-
mal physiology and some hypertensive states, as current evidence
indicates, interference with their synthesis or antagonism of their
effects should provide further insights, and possibly new targets
for antihypertensive drugs.
Anti-digoxin antibodies interact with a broad range of EDLFs
(114) and have been utilized in both experimental animals and
man, with some interesting results (87, 88, 115, 116). Although the
commercial preparation used in most of these studies is no longer
available, another commercially available preparation of digoxin
antibodies (DigiFab®) has similar if not identical cross reactivity
with EDLF (116–118). Finally, the ability of individual cardiotonic
steroids (CTS) to interfere with the effects of other CTS has added
another layer of complexity and suggests another novel approach
to the study of and possible therapy of various conditions in which
CTS may be involved (105).
Despite ongoing controversy regarding some of the details (58),
the hypothesis that an endogenous regulator(s) of the ouabain
binding site on the Na, K ATPase enzyme is involved in control
of the cardiovascular system has proved to be immensely fertile.
Further investigation of these endogenous regulators holds great
promise for a better understanding of cardiovascular physiology,
the pathophysiology of a diverse set of clinical disorders, includ-
ing hypertension, preeclampsia, chronic renal failure, congestive
heart failure, and cancer (70), and the intricate complexities of the
ouabain binding site (108, 119, 120).
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